Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an update.
ImmuneOnco Biopharmaceuticals has successfully completed the conversion of 14,114,006 Unlisted Shares into H Shares, with the listing of these shares commencing on May 15, 2025. This move increases the proportion of H Shares in the company’s capital structure to 97.29%, potentially enhancing liquidity and investor interest in the company’s stock.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative cancer immunotherapies. The company is listed on the Hong Kong Stock Exchange and aims to advance its market position in the biopharmaceutical industry.
Average Trading Volume: 5,814,819
Technical Sentiment Signal: Hold
Current Market Cap: HK$4.52B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.